AVALON VENTURES

Avalon Ventures is a San Diego-based venture capital fund focusing on seed and early stage companies in the wireless technology and life science industries, primarily in San Diego and California. Its current fund, Avalon Ventures VII, L.P., is worth $75 million.

Avalon Ventures is one of the longest-standing venture capital firms in San Diego, investing in life sciences and information technology opportunities since 1983 through six Avalon Ventures funds. The collective market capitalization of Avalon Ventures portfolio companies currently exceeds $5 billion. Co-investors in Avalon deals include well-known firms such as Kleiner, Perkins, Caufield & Byers and Versant Ventures.

www.avalon-ventures.com

NOVO A/S

Novo A/S is the holding company of the Novo Group and is wholly owned by the Novo Nordisk Foundation.  Novo A/S was established in 1999 to manage the assets and actively make investments on behalf of the Foundation.  Novo Ventures is recognized as a significant force within life science venture capital and is active in both Europe and North America. The Novo Ventures team consists of six partners in Copenhagen, one in London and two in San Francisco.

With an evergreen structure, Novo A/S annually invests approximately $85 million in venture capital in private life sciences companies and acts at a pace comparable to a traditional $400 million fund.  Novo A/S is not a corporate strategic fund; the group invests for financial rather than strategic returns.  In total, Novo A/S has more than $8 billion under management, which includes significant shareholdings in the independently operating and publicly listed companies Novo Nordisk A/S and Novozymes A/S.

www.novo.dk

PROSPECT VENTURE PARTNERS

Prospect Venture Partners is a venture capital firm, based in Palo Alto, California, with over $1 billion of capital under management, investing in outstanding biomedical technology and life science companies.

Prospect invests in companies with a broad range of development and financing requirements including incubating new companies, investing in first and second venture financing rounds and participating in later stage private and public companies with proven business models requiring expansion capital.  Prospect seeks to ultimately invest $10-20 million in each company, typically as a lead investor or as a co-lead in an investor syndicate.  First-round investments range from $500,000 to $10 million

www.prospectventures.com

VERSANT VENTURES

Versant Ventures is a leading healthcare-focused venture capital firm specializing in early-stage investments in medical devices, biotechnology and pharmaceuticals, healthcare services and healthcare information technology. The firm, founded in 1999, consists of a seasoned team of 11 managing directors with more than 115 years of venture capital investing experience and more than 145 years of operating experience.

Versant Ventures currently manages over $1 billion in committed capital, having raised its third fund in November 2005. Versant has investments in more than 70 companies.

www.versantventures.com